merged_eli-lilly-zepbound-price.txt
<other>I need to carefully read through the article and answer each question based solely on the facts provided, without drawing from external knowledge.</other>

<question_number>1</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs since compounded drugs are subject to far less oversight than traditionally approved medications</answer>

<question_number>2</question_number>
<answer>LillyDirect mimics the telehealth business model by connecting patients with providers through a telehealth platform and delivering vials directly to patients' doors, like compounded drugs prescribed by online startups</answer>

<question_number>3</question_number>
<answer>Lack of oversight and safety controls, as compounded drugs are subject to far less oversight than traditionally approved medications</answer>

<question_number>4</question_number>
<answer>To regain market share from telehealth companies offering compounded drugs, even if it means lower pricing, as suggested by experts who said the move could help Lilly regain customers currently getting compounded tirzepatide</answer>

<question_number>5</question_number>
<answer>Being on the FDA shortage list allows compounding pharmacies to legally make copycat versions of tirzepatide, but when removed from the shortage list, there should be no space for mass compounders</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>Concerns about older patients being attracted to the drugs despite unique risks including muscle mass loss that may make people over 65 more likely to suffer fractures or become frail</answer>

<question_number>8</question_number>
<answer>By positioning its vials as a safer option compared to non-FDA approved compounded medicines that are not controlled for safety, quality and effectiveness</answer>

<question_number>9</question_number>
<answer>Being listed as "in shortage" by the Food and Drug Administration</answer>

<question_number>10</question_number>
<answer>Lower pricing to regain market share from compounding pharmacies</answer>